Page last updated: 2024-09-05

lapatinib and Biliary Tract Cancer

lapatinib has been researched along with Biliary Tract Cancer in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Cheng, Q; Feng, F; Han, M; Jiang, X; Li, B; Li, F; Li, JY; Li, Z; Liu, C; Qin, H; Qiu, Z; Xiong, L; Xu, C; Yi, B; Yu, Y; Zhang, D	1
Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR	1
Belani, CP; Dancey, J; Gandara, DR; Gandour-Edwards, R; Iqbal, S; Kindler, HL; Lenz, HJ; Longmate, J; Lurje, G; Mack, PC; Ramanathan, RK; Singh, DA; Tanaka, M; Yen, Y	1
Bekaii-Saab, T; O'Neil, B; Peck, J; Villalona Calero, M; Wei, L; Zalupski, M	1

Trials

3 trial(s) available for lapatinib and Biliary Tract Cancer

Article	Year
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. British journal of cancer, 2014, May-27, Volume: 110, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome	2014
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:4 Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Humans; Lapatinib; Liver Neoplasms; Quinazolines; Survival Analysis	2009
HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology, 2012, Volume: 82, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate	2012

Other Studies

1 other study(ies) available for lapatinib and Biliary Tract Cancer

Article	Year
Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer patients with non‑radical resection: A real‑world study. Oncology reports, 2020, Volume: 43, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Class I Phosphatidylinositol 3-Kinases; Dasatinib; Deoxycytidine; ErbB Receptors; Everolimus; Female; Gemcitabine; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Organoplatinum Compounds; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Survival Rate; Treatment Outcome	2020

Article

Year

Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer patients with non‑radical resection: A real‑world study.

Oncology reports, 2020, Volume: 43, Issue:4

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Class I Phosphatidylinositol 3-Kinases; Dasatinib; Deoxycytidine; ErbB Receptors; Everolimus; Female; Gemcitabine; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Organoplatinum Compounds; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Survival Rate; Treatment Outcome

2020